EEF2K activity determines synergy to PI3K and MEK inhibitors in combination in cancer cells
Ontology highlight
ABSTRACT: To understand the mechanisms involved in synergy to PI3Ki + MEKi treatment, we performed a global phosphoproteomics analysis in 3 different cancer cell lines treated with a MEK inhibitor (Trametinib) and a PI3K inhibitor (Pictilisib) at 500 nM individually or in combination for one hour.
INSTRUMENT(S): Q Exactive Plus
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): Testis, Myeloblast, Peripheral Blood, Epithelial Cell, Breast
DISEASE(S): Acute Myeloid Leukemia,Embryonal Testis Carcinoma,Breast Cancer
SUBMITTER: Maruan Hijazi
LAB HEAD: Pedro Cutillas
PROVIDER: PXD018873 | Pride | 2022-04-25
REPOSITORIES: Pride
ACCESS DATA